Explanipedia

EXTH-59. Supporting development of novel brain tumour therapies through global collaboration: early insights from a novel therapeutics accelerator Open

Charlotte Aitken, Katie Bushby, Camille Goetz, Nicky Huskens, Karen Noble , et al. · 2025

Researchers developing novel therapies for brain tumours must navigate numerous challenges, including selection of suitable preclinical studies, safety, trial design, evolving regulatory landscapes, and securing sustained funding. To addre…

DDDR-52. Targeting tumour-astrocyte crosstalk for rational identification of novel therapeutic targets for medulloblastoma and atypical teratoid/ rhabdoid tumours Open

Harry Porter, Mohammed Diksin, Hasan Slika, Aanya Shahani, Cameron Alexander , et al. · 2025

Atypical Teratoid/Rhabdoid Tumours (ATRT) and Group 3 Medulloblastoma (MB) are aggressive paediatric brain tumours which mostly occur in infants and children. Due to the severity of off-target effects associated with chemo/radiotherapy in …

EPCO-32. THE M6A RNA METHYLATION EFFECTOR PROTEINS FXR1 AND CAPRIN1 ARE NOVEL POTENTIAL THERAPEUTIC TARGETS IN PAEDIATRIC HIGH-GRADE GLIOMAS Open

Ruman Rahman, Helen Miranda Knight, Stuart Smith · 2025

BACKGROUND Paediatric high-grade gliomas (pHGG) are aggressive and devastating malignant brain tumours. Disruption to N6-methyladenosine (m6A) RNA methylation is implicated in glioma development, but knowledge of mechanisms in pHGG is lack…

TMIC-80. Multi-omic integration reveals intra-tumour heterogeneity and identifies disulfiram and copper as a synergistic therapy in paediatric ependymoma Open

Alina Pandele, Alison Whitby, Sophie Lankford, Chiara Bastiancich, Ian Kamaly-Asl , et al. · 2025

Ependymoma (EPN) is the second most malignant paediatric brain tumour. The PF-A subgroup, associated with a hypoxic microenvironment and overexpression of the epigenetic regulator EZHIP, has a dismal survival rate of 50%, with clinical tri…

DDEL-23. Membrane proteomic profiling to identify candidate therapy targets for glioblastoma infiltration Open

Harry Porter, Shaylen Mistry, Robert Layfield, Ruman Rahman, Phoebe McCrorie · 2025

Intra-tumoural heterogeneity is a common driver of failure for novel IDH-wildtype glioblastoma (GBM) treatments, and many preclinical studies rely on cell lines established from the tumour core. Therefore, they fail to characterise the res…

RBIO-08. FLASH radiotherapy demonstrates superior control over glioblastoma spheroid area when compared to conventional radiotherapy Open

Riddhi Sharma, Sean M. Gettings, Will Timbury, Raymond Shek, Stuart Smith , et al. · 2025

BACKGROUND Glioblastomas (GBMs) are the most aggressive and prevalent primary brain tumour. Their high adaptability and resistance to therapy make them exceptionally challenging to treat. One key factor in GBM aggressiveness is a reliance …

Local delivery of Doxorubicin and Olaparib loaded injectable hydrogels with adjuvant radiotherapy improves survival in a glioblastoma in vivo model Open

Robert Cavanagh, Gary Shaw, Phoebe McCrorie, Amr ElSherbenny, Alina Pandele , et al. · 2025

Local drug delivery systems (LDDS) are a promising method to overcome challenges associated with chemotherapeutic treatment of brain tumours, namely poor blood-brain barrier penetration. Here we report a poly(ethyleneglycol)-poly(lactide)-…

EP18.01 GLOBAL COLLABORATION TO SUPPORT THE TRANSLATION OF BRAIN TUMOUR THERAPIES: EARLY IMPACT AND LEARNINGS FROM A NOVEL THERAPEUTICS ACCELERATOR. Open

Charlotte Aitken, K. Bushby, Camille Goetz, Nicky Huskens, Dione Kobayashi , et al. · 2025

BACKGROUND Researchers developing novel therapies for brain tumours must navigate numerous challenges, including selection of suitable preclinical studies, safety, clinical trial design, evolving regulatory landscapes, and securing sustain…

P02.22.A HYPOXIA-DRIVEN EGFR SIGNALING PROMOTES A QUIESCENT-ACTIVATION AXIS IN IDH-MUTANT LOW-GRADE GLIOMAS Open

Dola Das, Vatsalkumar Jariwala, Alina Pandele, Abdul Khader Mohammed, Tapas Das , et al. · 2025

BACKGROUND Hypoxia is a recognized driver of transcriptional heterogeneity in high-grade glioblastoma (GBM), yet its functional significance in low-grade gliomas (LGGs) remains poorly understood. We hypothesized that hypoxia orchestrates a…

DUAL COMBINATION DRUG TREATMENT FOR GROUP 3 MEDULLOBLASTOMA Open

Phoebe McCrorie, Harry Porter, Cara Moloney, Ruman Rahman · 2025

AIMS Group 3 medulloblastoma (MB) confers a 5-year survival of less than 45% in infants of <3 years and 58% in children. Radiotherapy poses signiﬁcant risk to young patients and is avoided in infants. Therefore, better treatment modalit…

AN INTERNATIONAL NOVEL THERAPEUTICS ACCELERATOR FOR BRAIN TUMOURS: EARLY IMPACT AND LESSONS LEARNED Open

Charlotte Aitken, Katie Bushby, Camille Goetz, Petra Hamerlik, Nicky Huskens , et al. · 2025

AIMS Developing a translational programme for brain tumours involves navigating numerous challenges, including robustness of preclinical studies, safety, clinical trial design, understanding and addressing regulatory require- ments, and fu…

MEMBRANE PROTEOMICS TO ELUCIDATE THE BASIS OF WIRELESS BIOELECTRONIC-INDUCED CELL DEATH IN GLIOBLASTOMAS Open

Miss Kayley Mulhall, Harry Porter, Shaylen Mistry, Bose Fashedemi, David J. Boocock , et al. · 2025

AIMS Isocitrate dehydrogenase wild-type glioblastomas (GBMs) are the most common form of brain cancer with a median survival of approximately 15 months, with less than 5% of patients surviving 5 years after diagnosis. GBMs are incurable wi…

EXPERIMENTAL DRUG DISCOVERY AND REPURPOSING VIA DRUGREP AND PYRX PREDICATED UPON THE GLIOBLASTOMA INﬁLTRATIVE MARGIN Open

Mohammed F. Shah, Stuart Smith, Emyr Bakker, Ruman Rahman · 2025

AIMS The inﬁltrative margin of GBM, a critical region indicative of residual disease, can be identiﬁed using 5- aminolevulinic acid (5ALA). This facilitates the detection of differentially expressed genes which potentially predict GBM recu…

MULTIOMIC INTEGRATION FOR ATYPICAL TERATOID RHABDOID TUMOURS TO IDENTIFY PLASMA MEMBRANE PROTEINS FOR THERAPEUTIC TARGETS Open

Shaylen Mistry, Harry Porter, Phoebe McCrorie, Anya Snary, Hannah Bailey , et al. · 2025

AIMS AT/RT’s - (Atypical Teratoid Rhabdoid Tumours) are rare, malignant hindbrain tumours, primarily diagnosed in children under three. Survival rates are low, radiation is generally avoided due to long-term health complica- tions in the d…

SINGLE-CELL METABOLIC PROﬁLING OF TUMOUR ASTROCYTE INTERACTIONS WITHIN A CO-CULTURE MODEL OF THE GLIOBLASTOMA INVASIVE MARGIN Open

Une Kontrimaite, Kei F Carver Wong, Phoebe McCrorie, Sandra Martinez Jarquin, Stuart Smith , et al. · 2025

AIMS Glioblastoma (GBM) is an aggressive brain tumour conferring poor prognosis and one of the highest recurrence rates despite multimodal treatment. The mechanisms underlying recurrence are not fully understood, but the tumour microenviro…

MULTI-OMIC INTEGRATION REVEALS INTRA-TUMOUR HETEROGENEITY AND IDENTIﬁES DISULﬁRAM AND COPPER AS A SYNERGISTIC THERAPY IN PAEDIATRIC EPENDYMOMA Open

Alina Pandele, Alison Whitby, Miss Sophie Lankford, Donald Macarthur, Ian Kamaly-Asl , et al. · 2025

AIMS Ependymoma (EPN) is the second most malignant paediatric brain tumor. The PF-A subgroup, associated with a hypoxic microenvironment and overexpression of the epigenetic regulator EZHIP, has a dismal survival rate of 50%, with clinical…

DECODING GLIOBLASTOMA INVASION: THE ROLE OF VOLTAGE-GATED POTASSIUM CHANNELS AND MICROTUBES IN POST-SURGICAL RECURRENCE Open

Ms Jeffy Joseph Vinohar, Ruman Rahman, Joern R. Steinert, Daniel G. Booth, Sébastien Serres · 2025

AIMS Isocitrate dehydrogenase wild-type glioblastoma (GBM) is an aggressive brain tumour with a high recurrence rate due to post-surgical residual disease. Poor prognosis is partly associated with inﬁltrative tumour cells forming networks …

Regional profiling reveals a distinct glioblastoma infiltrative margin proteome Open

Artur Kocoń, Stuart Smith, Benito Morentín, Luís F. Callado, Wayne G. Carter , et al. · 2025

Modular supramolecular polycations enable efficient delivery of RNA therapeutics and vaccines Open

Rafał J. Kopiasz, Hadijatou Sallah, Robert Cavanagh, S J Jones, Cara Moloney , et al. · 2025

We describe a modular, diverse and customisable supramolecular-materials platform which can deliver nucleic acids in vitro and in vivo with reduced immunogenicity and enhanced stability compared to lipid analogues. The chemistries deployed…

Correction: Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function Open

Shawn J. Macha, Balakrishna Koneru, Trevor A. Burrow, Charles Zhu, Dzmitry Savitski , et al. · 2025

Evolution of Preclinical Models for Glioblastoma Modelling and Drug Screening Open

Grace Thomas, Ruman Rahman · 2025

Purpose of Review Isocitrate dehydrogenase wild-type glioblastoma is an extremely aggressive and fatal primary brain tumour, characterised by extensive heterogeneity and diffuse infiltration of brain parenchyma. Despite multimodal treatmen…

Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells Open

Sheila Barrios-Esteban, Sonia Reimóndez-Troitiño, Pablo Cabezas‐Sainz, María de la Fuente, Laura Sánchez , et al. · 2025

Isocitrate dehydrogenase wild-type glioblastoma is the most aggressive primary brain tumor classified as grade 4 of malignancy. Standard treatment, combining surgical resection, radiotherapy, and chemotherapy, often leads to severe side ef…

Pentablock thermoresponsive hydrogels for chemotherapeutic delivery in a pancreatic cancer model Open

Amr Elsherbeny, Hulya Bayraktutan, Nurcan Gümüş, Phoebe McCrorie, Andrés García-Sampedro , et al. · 2025

A thermoresponsive hydrogel is synthesised with biodegradability, in situ swelling, and drug release appropriate for anti-cancer agents. We demonstrate retention of the new hydrogel in vivo enabling local drug release in a pancreatic cance…

Metabolomic characterisation of the glioblastoma invasive margin reveals a region-specific signature Open

James Wood, Stuart Smith, Marcos Castellanos‐Uribe, Anbarasu Lourdusamy, Sean May , et al. · 2024

REST-dependent glioma progression occurs independently of the repression of the long non-coding RNA HAR1A Open

Ella V. Waters, Perla Pucci, Ruman Rahman, Anna P. Yatsyshyna, Harry Porter , et al. · 2024

The long non-coding RNA (lncRNA), HAR1A is emerging as a putative tumour suppressor. In non-neoplastic brain cells, REST suppresses HAR1A expression. In gliomas REST acts as an oncogene and is a potential therapeutic target. It is therefor…

Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma Open

Riccardo Serra, Stuart Smith, Jonathan Rowlinson, Noah Gorelick, Cara Moloney , et al. · 2024

Background There is increased pan-cancer specific interest in repurposing the poly adenosine diphosphate-ribose polymerase-1 (PARP-1) inhibitor, olaparib, for newly diagnosed or recurrent isocitrate dehydrogenase wild type glioblastoma. We…

Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance Open

P. Malhotra, Ruman Rahman · 2024

Isocitrate dehydrogenase wild-type glioblastoma, a Grade 4 malignant brain neoplasm, remains resistant to multimodal treatment, with a median survival of 16 months from diagnosis with no geographical bias. Despite increasing appreciation o…

Bipolar electrochemical growth of conductive microwires for cancer spheroid integration: a step forward in conductive biological circuitry Open

Andie Robinson, Craig McBeth, Ruman Rahman, Richard Hague, Frankie J. Rawson · 2024

Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine Open

Isabella Sanchez, Ruman Rahman · 2024

ATRT-01. MODELLING ATYPICAL TERATOID/ RHABDOID TUMOUR AND HEALTHY BRAIN CROSSTALK Open

Harry Porter, Phoebe McCrorie, Mohammed Diksin, Cara Moloney, Richard G. Grundy , et al. · 2024

BACKGROUND Atypical Teratoid/Rhabdoid Tumours (ATRT) are aggressive paediatric brain tumours which mostly occur in the first three years of life and which rapidly recur after surgical resection. There has been debate over the use of cytoto…

Ruman Rahman YOU? Author Swipe